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Hypertension has been recognized as an important health issue in the pediatric population over the past
years. This emphasizes the need for an organized and effective plan for diagnosis and management. This
review provides information to guide physicians through a structured approach to (1) screen children for
hypertension during routine visits; (2) use normative blood pressure tables for diagnosis and classification;
(3) perform a clinical evaluation to identify the presence of risk factors, comorbidities and/or target organ
damage; and (4) initiate an individualized plan of care that includes follow-up blood pressure
measurement, therapeutic lifestyle changes and - if necessary - pharmacological therapies.
Keywords: Hypertension, Children, Adolescents, Blood pressure, Treatment
Introduction and Purpose
There is growing evidence that mild blood pressure
(BP) elevations in children and adolescents are much
more common than it was thought before.1 Recent
reports indicate that hypertension now affects
between 3 and 5% of the pediatric population.2 This
makes hypertension one of the most common chronic
diseases of childhood, especially in adolescence.3
Longitudinal studies have made it clear that BP
abnormalities during childhood do translate into
adult hypertension.1–6 Where there was in the past a
predominance of secondary hypertension in children,
associated with renal disorders and/or drug therapy,
there is now an increasing frequency of essential
hypertension.
There are two major reference frames for the
management of hypertension in children: The Fourth
Report on the Diagnosis, Evaluation, and Treatment
of High Blood Pressure in Children and Adolescents
from the National Heart, Lung and Blood Institute6
and the revised guidelines of the European Society of
Hypertension.1 It should be noted that these pediatric
guidelines are much more expert than evidence based,
since they are supported by only few observational
and interventional trials in contrast with the adult
guidelines.1 The remoteness of incident cardiovascu-
lar events from BP values many years beforehand
makes the relationship of BP values with events
hardly feasible. Consequently, many of the classifica-
tions and recommendations in children are based on
statistical considerations, and result from assump-
tions rather than the results of experiments or result
from extrapolations from evidence obtained in
adults.1
Increased BP at pediatric age is an underestimated
problem in primary and secondary care in Belgium.
Major attention to this topic is only given in
specialized pediatric nephrology and cardiology
journals. Therefore there is a need to translate these
international guidelines into a Belgian setting.
Definition and Classification of Hypertension
Diagnostic criteria for elevated BP in children are
based on the concept that BP in children increases
with age and body size, making it impossible to utilize
a single BP level to define hypertension, as done in
adults.1 The definition of elevated BP for children is
based on percentiles derived from population studies
of healthy children. Extensive pediatric normative
data on auscultatory clinic measurements have been
provided for the United States, based on more than
70 000 children, from the Task Force for Blood
Pressure in Children.5-7 A few national studies were
undertaken in Europe, but were unable to overrule
the Task Force for Blood Pressure1 as reference, even
for the European setting,8 since they included less
patients, and differences were only mild and therefore
hardly clinically relevant.
Normal BP in children is defined as systolic blood
pressure (SBP) and diastolic blood pressure (DBP)
less than 90th percentile for age, sex and height,
whereas hypertension is defined as SBP and/or DBP
persistently 95th percentile or more, measured on at
least three separate occasions with the auscultatory
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method. Children with average SBP or DBP 90th
percentile or more but less than 95th percentile are
classified as having high-normal blood pressure.
Adolescents with BP 120/80 mmHg or more even if
less than 90th percentile are also considered as having
high-normal BP.1,6 Redwine et al. showed that
having high-normal BP is a higher risk of developing
hypertension.2,3 Additionally, the Fourth Report
provides criteria for staging the severity of hyperten-
sion in children and adolescents in stage 1 hyperten-
sion and stage 2 hypertension, which can be used
clinically to guide evaluation and management.1,3,6
Children with stage 2 hypertension should be
evaluated and treated more quickly and/or intensively
than those with a lower degree of BP elevation
(Table 1).1
Diagnostic Evaluation
Blood pressure measurement
Patients with hypertension may show symptoms such
as headache, malaise, nose bleeding and palpitations
but hypertension is predominantly an asymptomatic
condition, which can only be diagnosed by routine
measurement of BP.3 Children above three years of
age who are seen in a medical setting should have
their BP measured.3,6,9 Younger children should have
their BP measured in special circumstances: history of
prematurity, congenital heart disease, known renal
disease or urologic malformations, malignancy, solid-
organ transplant, other systemic illnesses and drugs
known to be associated with elevated BP.6 The
diagnosis of hypertension should be based on multiple
office BP measurements, taken on separate occasions
over a period.1 Although office BP should be used as
reference, BP values obtained out of office may improve
the evaluation in untreated and treated individuals.1
Office or clinic blood pressure
Office BP measurement has provided the basis for the
present knowledge of the potential risk associated
with hypertension and has guided management
for many years.1 The available reference values for
defining BP classes have been obtained by the
auscultatory method (Korotkoff sounds-based mea-
surement).1 These BP standards, including the 50th,
90th, 95th and 99th percentiles by gender, age, and
height are publicly accessible on http://www.nhlbi.
nih.gov/guidelines/hypertension/child_tbl.pdf.6 Oscil-
lometric devices, which do not measure SBP and
DBP directly but calculate BP from pressure oscilla-
tions detected in the arm cuff, have been introduced
more recently.1,2 It should be noticed that values
obtained by the oscillometric method are generally
higher than values obtained by the auscultatory
method. Few oscillometric devices have been success-
fully validated using an established protocol. The
continuously updated data available on monitor
validation for children is found at www.dableduca-
tional.org.1 Another important issue to consider in
the measurement of BP in children, is that appro-
priate cuff size can vary substantially among children
of the same age. The cuff bladder should have a width
that covers approximately two-thirds of the upper
arm and a length that encircles at least 80% of the
upper arm, preferably 100%.6 Preferably, BP is
measured at the right arm, after the patient has been
sitting for 5 minutes, feet on the floor and right arm
supported with cubital fossa at heart level.6 The right
arm is preferred in repeated measures of blood
pressure for consistency and comparison with stan-
dard tables and because of the possibility of coarcta-
tion of the aorta, which might lead to false (low)
Table 1 Classiﬁcation of hypertension in children and adolescents6
Systolic or diastolic
blood pressure (if
systolic and diastolic
categories are different,
categorize by the
higher value)
Frequency of BP
measurement
Normal ,90th Recheck at next scheduled
physical examination
High-normal blood pressure 90th to 95th or if BP
exceeds 120/80 mmHg
even if ,90th percentile
Recheck in 6 months
Stage 1 hypertension 95th–99th percentile
plus 5 mmHg
Recheck in 1–2 weeks or
sooner if symptomatic; if
persistently elevated on
two additional occasions,
evaluate or refer to a pediatric
nephrologist/cardiologist
within 1 month
Stage 2 hypertension .99th percentile plus
5 mmHg
Evaluate or refer to a pediatric
nephrologist/cardiologist within
1 week or immediately if the
patient is symptomatic
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readings in the left arm.6 Moreover, a four extremi-
ties BP check is mandatory in a child with hyperten-
sion to evaluate for coarctation of the aorta, which is
one of the causes of secondary hypertension.10 If the
leg BP is lower than the arm BP (in supine
position),11 or if femoral pulses are week or absent,
coarctation of the aorta may be present.6
Ambulatory blood pressure
Although office BP is still the reference for the
diagnosis of hypertension, ambulatory BP measure-
ment (ABPM) is now increasingly recognized as
being indispensable to the diagnosis and management
of hypertension, in children of 5 years or older.6,9,12
It has contributed significantly to ‘unmask’ BP
phenomena, unlikely to be identified by office BP.1,6
These have included the dipping and non-dipping
patterns of nocturnal BP, BP values in the hyperten-
sive range in the office but not out-of-office (white-
coat hypertension)1,3,12 or, vice versa, in the normo-
tensive range in the office but not out-of-office
(masked hypertension).1,12 Reference values provided
by the German Working Group on Pediatric Hyper-
tension are currently considered the best available
data for pediatric ABPM.13,14 ABPM is often used in
randomized clinical trials of BP-lowering drugs (in
adults) to compare antihypertensive efficacy between
therapeutic agents and to assess 24-hour BP control,
including improvement in nocturnal dipping with
treatment. Use of ABPM, therefore, provides addi-
tional information on circadian BP control that may
alter selection and dosage of an antihypertensive
medication.12
Home blood pressure
Concerning home BP measurements, evidence in
children and adolescents is limited. In children, home
BP has superior reproducibility than office BP has
and is similar to that for ABPM. Home monitoring
for 6–7 days with duplicate morning and evening
measurements is recommended. Home BP in children
is lower than daytime ambulatory PB, probably due
to a high level of physical activity during the day.1
Evaluation for risk factors and for secondary
hypertension
In order to identify possible causes of hypertension,
the first investigations in the child with hypertension
should include: a complete (family) history, physical
examination, blood exam, urinalysis and ultrasound
of kidney and heart.1
Primary hypertension often clusters with other risk
factors.6 Considerable advances have been made in
recent years in identifying conditions often associated
with and considered responsible for high BP in
children and adolescents.1 Overweight is probably
the most important of the conditions associated with
elevated BP in childhood1,4 and accounts for more
than half of the risk for developing hypertension.1
Birth size and postnatal growth have also been
recently implicated in the development of high
BP and adult cardiovascular disease.1 Furthermore,
dietary habits early in life, and particularly high salt
intake,15 have been implicated as factors favoring
higher BP values.1,4 Studies on racial differences
showed that African-American children had a higher
prevalence of overweight/obesity and left ventricle
hypertrophy (LVH) than non-African-American
children.4,7 Sleep disorders including sleep apnea are
associated with hypertension, coronary disease, heart
failure and stroke in adults. Although limited data
are available, they suggest an association of sleep-
disordered breathing and higher BP in children.6
Consideration of these associated risk factors and
appropriate evaluation in those children in whom the
hypertension is verified, are important in planning
and implementing therapies.
Sustained hypertension in children and adolescents
is classified as secondary when a specific cause can be
found, which can sometimes be corrected with
specific intervention.1 The most common causes of
secondary hypertension differ according to the age
of the children.16 In very young children (,6 years),
hypertension is most often the result of renal paren-
chymal diseases such as glomerulonephritis, renal
scarring, polycystic kidney, renal artery stenosis and
renal dysplasia.1,5 Hypertension is present in approxi-
mately 50% of children with chronic kidney disease.17
Both high BP and increased proteinuria are pre-
dictors of the progression of renal disease among
children with chronic kidney disease.17 The most
common cardiovascular cause of hypertension is
coarctation of the aorta and Turner’s syndrome. In
all ages, following rare but identifiable causes of
hypertension should be considered: endocrine diseases
(hyperthyroidism, Cushing’s syndrome, primary hype-
raldosteronism) and some endocrine tumors (pheo-
chromocytoma and neuroblastoma), and food or drugs
that raise BP (liquorice, oral contraceptives, steroids,
non-steroidal anti-inflammatory drugs, cyclosporin).16
Evaluation of target-organ damage
Once hypertension is confirmed, organ damage
evaluation should include heart, great vessels and
kidney, due to the importance of subclinical organ
damage as an intermediate stage in the continuum of
vascular disease.1,3 Subsequently, evaluation of organ
damage is also useful as an intermediate endpoint for
monitoring treatment protection.1 Neurologic and
ophthalmologic clinical evaluation are indicated in
severe hypertension.1 The most useful and relevant
way (and primary tool) to evaluate target-organ
damage is by assessing left ventricular mass using
echocardiography.3,5,6,9,16 Left ventricular hypertrophy
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can result from prolonged exposure of the left ventricle
to increased afterload caused by increased systemic BP.3
The prevalence of LVH in children and adolescents
with arterial hypertension has been found to be around
20–41%.18 Identification of LVH may suggest the need
for more urgent and more aggressive treatment of
hypertension.3,5
Antihypertensive Treatment
When to initiate antihypertensive treatment
As in adults, also in children, the decision to initiate
antihypertensive treatment should not be taken on
BP levels alone, but should consider the presence or
absence of target organ damage, other (cardiovascu-
lar) risk factors or diseases such as obesity, renal
diseases or diabetes.1 It should be stressed that if
the patient is symptomatic, immediate referral and
treatment are indicated.19 In children with proven
secondary hypertension, specific treatment of the
underlying disease must be initiated immediately after
detection.1 In children with primary hypertension,
antihypertensive therapy should first target the risk
factors for BP elevation (i.e. overweight, increased
salt intake, low physical activity).1
Goal of Treatment
Blood pressure target in the general hypertensive
population
Pediatric BP targets are commonly defined popula-
tion based, in the absence of prospective long-term
studies linking children BP levels to cardiovascular
outcomes. The 95th percentile is commonly used as a
cutoff for defining hypertension in children and
adolescents without renal comorbidity. The recom-
mendations of the European Society of Hypertension
state that this provides a rationale for targeting
children and adolescents with primary hypertension
to a BP below the 95th but also mention that is
probably wiser and safer to aim at a BP below the
90th percentile.1
Blood pressure target in renal disease
The international guidelines advocate to target a BP
,50th percentile in hypertension associated with
renal disease. This statement is to some extent
supported by the prospective randomized ESCAPE
trial17: strict BP control aiming for a 24-h target
below the 50th percentile of mean arterial pressure by
the addition of other antihypertensive agents to
angiotensin converting enzyme inhibitor (ACEI)
therapy resulted in a better 5-year renal survival,
despite a return of proteinuria toward pretreatment
values. Analysis by achieved BP levels showed similar
renal outcomes with any 24-h BP below the 75th
percentile, contrasting with significantly reduced 5-
year renal survival in patients exceeding the cutoff
level. Proteinuria appears to be an important
modifier of the renoprotective efficacy of intensified
BP control. Admittedly, only a minority of patients in
the different studies reached values ,50 percentile.1
Therapeutic Strategies
Life style changes
Non-pharmacological treatment of hypertension
includes weight loss, aerobic exercise, restriction of
salt intake and stress reduction.5 While these therapies
may be effective in reducing the BP to the targeted
levels, pharmacologic therapy will need to be con-
sidered if they do not.5 Life style changes should not
only precede but also accompany pharmacological
treatment.1
Therapeutic therapy
Therapeutic orphans
A major issue related to the use of antihypertensive
medications in young people is the availability of
safety and efficacy data.3 Historically, few drug trials
were conducted in children, with the consequence that
many drugs had to be used empirically, without the
benefit of specific pediatric efficacy, safety, or dosing
information.3 Besides, there is lack of suspensions or
other age appropriate drug formulations.20 In 2007,
the European authorities implemented the European
Regulation after realizing that children also have the
right to be treated with drugs that have been studied in
children.1 The goal of this Regulation of medicinal
products for pediatric use is to increase the availability
of medicines authorized for children, as well as to
improve the information on the use of medicinal
products in the pediatric population.1 The Pediatric
Regulation requires manufacturers to study medica-
tions in children to be able to market them in Europe.
Despite this initiative, reliable pediatric data obtained
from controlled studies with older compounds with
expired patent protection are still not available.1,6
Hopefully, the Pediatric Use Marketing Authorization
will help resolve this problem, at least in part.1 For the
time being, the present recommendations on pharma-
cotherapy in hypertension are based on few industry-
sponsored studies, and mostly on single-center case
series, collective clinical experience, expert opinion and
extrapolation from data obtained in adults.1
Like in adults, choice of antihypertensive agents
can include ACEIs, angiotensin receptor antagon-
ists, calcium antagonists, beta-blockers and diuretics
(Table 2).1,5,6 Although many individual antihyper-
tensive compounds have been studied in the pediatric
age group, no pediatric studies comparing different
agents have been conducted.3,5,6,21 This situation
leaves the prescriber without evidence-based guidance
for choice of drug.3,5 The etiology of the hypertension,
the anticipated benefits for the child, and the potential
adverse effects should guide the choice of medication.5
Certain co-morbidities that favor certain classes of
drugs include the use of an ACEI or angiotensin-II
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receptor blocker (ARB) in patients with diabetes
and microalbuminiuria or proteinuric renal disease.
Calcium channel blockers are also a good option in
patients with diabetes or metabolic syndrome because
they improve insulin sensitivity. Beta-blockers and
calcium channel blockers should be considered in
patients with migraine. In general, black children and
adolescents do not respond well to ACEIs at standard
doses. Severe symptomatic hypertension should be
treated with intravenous antihypertensive drugs.6
Monotherapy versus combination therapy
It is reasonable that in children, treatment should be
started with a single drug administered at a low dose
in order to avoid rapid fall in BP. If BP does not
decrease sufficiently after a few weeks, usually four to
eight weeks, an increase to the full dose should be
initiated. Once the highest recommended dose is
reached, or if the child experiences side effects from
the drug when increasing the dose, a second drug
from a different class should be added.1
Table 2 Recommended initial doses adapted from Lurbe et al.,1 Kavey et al.,3 and Flynn and Daniels.20 The maximum
recommended dose should not be exceeded.
Class Drug
Starting oral
dose Interval
Maximum
daily oral
dose
Labeling for
hypertension
in children
with dosing
advise in
Belgium
Availability of
pediatric
formulation
in Belgium27
Diuretics Chlorthalidoneu 0.3 mg/kg/day Once daily 2 mg/kg
up to 50 mg
Yes No
Furosemide 0.5–
2 mg/kg/dose
Once to
twice daily
6 mg/kg Yes No
Hydrochlorothiazide Not available in
Belgium
Spironolactone 1 mg/kg/day Once to
twice daily
3.3 mg/kg
up to 100 mg
Yes No
Beta-
adrenergic
blockers
Atenolol 0.5–
1 mg/kg/day
Once to
twice daily
2 mg/kg
up to 100 mg
No No
Metoprolol 1–2 mg/kg/day Twice daily 6 mg/kg
up to 200 mg
.6 y No
Propanolol 1 mg/kg/day Twice to
three times
daily
16 mg/kg
up to 640 mg
No No
Calcium
channel
blockers
Amlodipine 0.06 mg/kg/day Once daily 0.3 mg/kg
up to 10 mg
.6 y No
Felodipine 2.5 mg/day (no
dose referenced
to weight available)
Once daily 10 mg No No
Extended-
release
nifedipine
0.25–
0.5 mg/kg/day
Once to
twice daily
3 mg/kg
up to 120 mg
No No
Angiotensin-
converting
enzyme
inhibitors
Captopril 0.3–
0.5 mg/kg/dose
Twice to
three times
daily
6 m/kg
up to 450 mg
No No
Enalapril 0.08 mg/kg/day Once daily 0.6 mg/kg
up to 40 mg
.20 kg No
Fosinopril 0.1 mg/kg/day Once daily 0.6 mg/kg
up to 40 mg
No No
Lisinopril 0.08 mg/kg/day Once daily 0.6 mg/kg
up to 40 mg
.20 kg No
Ramipril 2.5–
6 mg/day
Once daily 20 mg No No
Angiotensin-
receptor
blockers
Candesartan 0.16–
0.5 mg/kg/day
Once daily 32 mg .6 y No
Irbesartan 75–150 mg/day
(no dose referenced
to weight available)
Once daily 300 mg No No
Losartan 0.75–
1.4 mg/kg/day
Once daily 1.4 mg/kg
up to 100 mg
.6 y and .20 kg Yes
Valsartan 1.3 mg/kg/day Once daily 2.7 mg/kg
up to 150 mg
.6 y Yes
Note: u Standard dose of chlortalidone has been decreased in adults because of side effects. Use in children should also be cautious
with use of the lowest effective dose and monitoring of serum electrolytes.
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Beta-adrenergic blockers (BBs)
Beta-adrenergic antagonists reduce the effect of endo-
genous catecholamines on beta-adrenergic receptors.5
Although BBs were among the first and most widely
used antihypertensive medications in children, there
are limited studies evaluating BBs in children.5
Characteristics that distinguish one BB from another
include cardioselectivity, alpha-adrenergic activity,
hydrophilic and lipophilic properties and intrinsic
sympathicomimetic activity.5 The variability of phar-
macologic properties of drugs in this group and
characteristics of each individual drug influence the
selection of medication.5 There is limited information
on efficacy and safety of the newer vasodilating beta-
blockers like carvedilol (non-selective beta-blocker
with alpha1-blocking property) and nebivolol (selec-
tive beta1-blocker that has vasodilatory properties
through the NO mechanism) for the treatment of
hypertension in children.22
Possible side effects attributable to BBs include
bradycardia, anorexia, asthma exacerbations, night
terrors, heart block, fatigue, cold extremities, and
sexual dysfunction.5 It is important to note that BBs
are associated with changes in carbohydrate and lipid
metabolism; and can inhibit the warning signs of
hypoglycaemia. For patients with labile glycemic
control, beta-adrenergic antagonists, including those
that are cardioselective, should be avoided.21,23 BBs
are not considered first line therapy in adolescents
because of their interference with physical activity.
Calcium channel blockers (CCBs)
Calcium channel blocking antihypertensives are a
heterogeneous group of compounds that inhibit
the influx of extracellular calcium into the cellular
membrane of the smooth muscle and other contrac-
tile cells by blocking the transmembrane transport of
calcium. This results in reduced contractility and
arteriolar smooth muscle tone in a dose-dependent
fashion. Dihydropyridines are the major class of
CCBs used to treat essential hypertension in children
because of their relative selectivity for arteriolar
smooth muscle.5 These include amlodipine, isradi-
pine, felodipine, nicardipine and nifedipine. They
have shown efficacy in treating hypertension in
children. Nicardipine and isradipine have been des-
cribed to cause cerebral vasodilation and must be
used cautiously in children with intracranial pathol-
ogy if at all.24,25 On theoretical grounds this should
be extended to all calcium channel blockers.24 The
most common adverse effects reported with the use of
CCBs include peripheral edema, dizziness, flushing,
nausea, headache, and postural hypotension. Other
reported adverse events include gingival hyperplasia,
chest pain, nausea and vomiting, and reflex tachy-
cardia seen with nifedipine. Side effects are seen more
commonly as maximum dosages of the drugs are
reached.5
The non-dihydropyridines are rarely used for the
treatment of essential hypertension in children and
adolescents because of their effects on cardiac
conduction and contractility.5
Angiotensin-converting enzym inhibitors
ACEIs act on the renin-angiotensin system by
preventing the conversion of angiotensin I to angio-
tensin II. Angiotensin II is a vasoconstrictor that also
causes aldosterone secretion.5,21 In addition, ACEIs
cause a decrease in bradykinin metabolism, which is
thought to play also a role in the antihypertensive
effects of these medications.21 ACEIs are widely used
in the management of both primary and secondary
hypertension in pediatric patients. In general, they
have few adverse effects in standard doses and have
convenient dosing schedules to improve adherence.5
The side effects of ACEIs in children do not differ
from those seen in adults. They include hypotension,
cough, hyperkalemia and elevated creatinine.5,21 Moni-
toring of serum electrolytes and creatinine are recom-
mended with initiation of therapy and periodically to
monitor the potassium and creatinine. Other adverse
reactions include angioedema, headache, anemia, tach-
ycardia, vertigo, dyspnea, rash and leucopenia.5 ACEIs
are contraindicated during pregnancy and should
be used cautiously in those of child-bearing age.21
Maternal use during pregnancy is associated with
profound fetal hypotension, growth restriction, pul-
monary and renal hypoplasia, anuria and neonatal
death.5
Angiotensin -II receptor blockers (ACEIs)
ARBs act on the renin-angiotensin system by
blocking the binding of angiotensin II to the AT1-
subtype of the angiotensin-II receptors in blood
vessels and other tissues. Unlike ACEIs, ARBs have
minimal effect on bradykinin metabolism.21 Data on
the effects of ARBs in hypertensive children have
accumulated recently. Several studies have demon-
strated the efficacy of ARBs in the treatment of
hypertension in children. The ARBs irbesartan,
candesartan, valsartan, and losartan have shown to
lower SBP and DBP. Irbesartan, candesartan and
losartan have also shown to decrease proteinuria by
over 50% as well. ARBs are generally well tolerated,
with a favorable side effect profile. Side effects
reported included rhinitis, urinary and gastrointest-
inal infections, headache, dizziness, blurred vision,
fatigue, anemia and hyperkalemia. Other adverse
reactions reported include rash and pruritus, hyper-
glyceridemia, leucopenia and thrombocytopenia.
Although cough and angioedema occur in patients
with ARBs, they are observed less frequently than in
patients treated with ACEIs.
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The same precautions should be taken in pregnancy
and in women of child-bearing age as with ACEIs.
Similar congenital malformations seen with ACEI
exposure during pregnancy have been reported.5
Diuretics
Diuretics are used primarily as a second medication
when adequate BP has not been attained with
monotherapy especially in adolescents and in children
with renal disease with high volume states. There is a
paucity of studies examining the use of diuretics for
essential hypertension in children. The two types
primarily used are thiazides and loop diuretics.
Thiazide diuretics exert their effect on the distal
tubule in the kidney to decrease sodium and water
reabsorption and increase potassium secretion in an
ion exchange mechanism by inhibiting the sodium-
chloride membrane transporter. With long-term use,
the thiazides produce vasodilation. Their efficacy is
dependent on the glomerular filtration rate. They are
most efficacious when the glomerular filtration rate
(GFR) is .50 ml/min and ineffective when the GFR
is ,30 ml/min. Thiazide diuretics produce elevations
in blood glucose and insulin levels. Loop diuretics
exert their effect at the ascending limb of the loop of
Henle by decreasing the reabsorption of sodium and
water by inhibiting the sodium–potassium–chloride
membrane transporter. They also increase renal blood
flow by reducing renovascular resistance. Loop diure-
tics are more potent than thiazides but their efficacy
also decreases as GFR is reduced.5 They are used
primarily in patients with underlying renal disease, fluid
retention and renal insufficiency (30–50 ml/minute).1,21
Common side effects of diuretics relate to their
effects on fluid and electrolyte balance, therefore
serum electrolytes and creatinine should be mon-
itored. Hypokalemia, volume contraction6hypoten-
sion, anorexia, nausea and vomiting, pancreatitis and
elevated uric acid levels have been reported as well as
ototoxicity with the use of loop diuretics.5
No clinical trials were found to support spirono-
lactone’s role in pediatric hypertension, although it is
used in the treatment of hypertension secondary to
diseases characterized by mineralocorticoid excess and
as concomitant therapy in children taking medications
that increase aldosterone secretion such as CCBs and
vasodilators. 21,23
Other antihypertensive agents
No pediatric studies have been conducted for direct
vasodilators, centrally acting agents or alpha-1
receptor antagonists, despite their long history of
clinical use in the pharmacological management of
hypertension in children.1
Long-term Follow-up
As in adults, antihypertensive therapy in children and
adolescents must be monitored closely, both for efficacy
and for potential adverse effects. BP should be
measured in the office every 2 to 4 weeks until good
control is achieved. Once control is achieved, then office
BP measurement every 3 to 4 months is appropriate.
Periodic laboratory monitoring may also be required,
particularly if a diuretic or agent affecting the renin-
angiotensin system is prescribed, or if the hypertensive
child or adolescent has underlying renal disease as the
cause of their hypertension.3 Since nocturnal and/or
circadian rhythm of BP are probably directly correlated
with long-term target damage, 24 hours BP measure-
ment for monitoring is highly recommended.18
Adherence to treatment is an important long-term
issue in the treatment of hypertension in children
and adolescents, because most patients have so few
symptoms. In adolescents, this situation is particu-
larly difficult because they often do not like to take
their medications and do not like to be perceived as
different from their peers. If BP control can be
achieved with a single drug that is taken once a day,
this improves the likelihood of compliance and this
should be taken into consideration when the initial
agent is chosen. The adverse effect profile of the
medication may also affect adherence.3
Conclusion
Although most of the adverse outcomes of hyperten-
sion occur in adulthood, there is now more clear
recognition of the relationship between childhood
and subsequent adult BP and identification of
subclinical end-organ damage in children, adoles-
cents, and adults. This should increase the focus by
pediatricians and general practitioners on detection
of hypertension and reinforce the efforts to achieve
BP reduction via non-pharmacological and pharma-
cological treatments in children with hypertension.
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